Medicare now pays for Lucid Diagnostics’ ESAGard test, enabling commercial acceleration. Third-quarter revenue was $1.2 million from 2,871 tests, while October volume exceeded 1,800 and pro forma cash reached approximately $33 million.
LUCD · Lucid Diagnostics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Lucid Diagnostics Inc. reported a $45.0 million net loss attributable to common stockholders for nine months ended September 30, 2026, raising substantial doubt about continuing as a going concern. A subsequent Series C preferred stock sale raised approximately $15.0 million.
Lucid Diagnostics Inc. said EsoGuard is now fully reimbursed nationwide by Medicare, received its first Medicare payments in October at $1,938.01 per test, and recorded $1.2 million in third-quarter revenue.
Lucid Diagnostics Inc. sold 15,000 shares of Series C Convertible Preferred Stock at $1,000 per share on October 21, 2026, generating approximately $15.0 million. The stock pays 20% per annum dividends and converts at $0.3519.
Lucid Diagnostics Inc. received a Nasdaq notice on October 12, 2026 that its common stock traded below the $1 minimum bid price for 30 consecutive business days, giving it until April 12, 2027 to regain compliance.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Medicare reimbursement, record October test volume, new financing, and expanding commercial and VA coverage mark a positive commercial acceleration. However, third-quarter revenue declined sequentially from $1.5 million to $1.2 million, the company reported a $6.7 million GAAP net loss, the Series C carries a 20% stock-paid dividend with approximately 330 million fully diluted shares, and the draft MolDX LCD remains unpublished amid an administrative backlog.
- + Medicare payments for EsoGuard began in October at $1,938.01 per test, with every allowed claim paid at the full rate.
- + October test volume reached a record monthly level of more than 1,800 tests.
- + A $15 million financing gave management confidence that the company has sufficient runway for commercial acceleration and revenue growth.
- + Quarterly cash burn was $10.2 million, the lowest of the last four quarters.
- + Five Concert client health plans are expected to adopt the EsoGuard coverage policy by year-end.
- + Lucid launched its first two VA programs and expects VA to become a meaningful long-term contributor.
- − Third-quarter revenue was $1.2 million, essentially flat year over year and down from $1.5 million in the second quarter.
- − The company reported a $6.7 million GAAP net loss attributable to common stockholders in the third quarter.
- − Cash and cash equivalents were $18.0 million at September 30, 2026, compared to $34.7 million at December 31, 2025.
- − The Series C preferred carries a 20% annual stock-paid dividend, and fully diluted shares are approximately 330 million.
- − The pending draft MolDX LCD remains unpublished amid a persistent administrative backlog.
- − Only 39% of adjudicated third-quarter claims resulted in an allowable amount from the insurance company.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Clinical Laboratory Fee Schedule rate | $1,938.01 | October | — |
| EBITDA non-GAAP | -31.8M | For the nine months ended September 30, 2026 | — |
|
|
|||
| EsoGuard test volume | 1,800 | October | — |
| EsoGuard tests | 2,871 | 3Q26 | — |
| Net operating expenses non-GAAP | 35.84M | For the nine months ended September 30, 2026 | — |
|
|
|||
| Non-GAAP adjusted (loss) non-GAAP | -31.91M | For the nine months ended September 30, 2026 | — |
|
|
|||
| Non-GAAP adjusted (loss) income per share non-GAAP | -$0.06 | the three months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LUCD
this stock
Lucid Diagnostics Inc.
|
$92.95M | -58.8% | +79.0% | — | 7.2% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 21
Lucid Diagnostics Inc. reported a $45.0 million net loss attributable to common stockholders for nine months ended September 30, 2026, raising substantial doubt about continuing as a going concern. A subsequent Series C preferred stock sale raised approximately $15.0 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LUCD | +12.8% | -6.1% | -59.5% | +10.9% | -58.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +10.3% | -4.9% | -60.0% | +11.1% | -69.4% |